Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Directorate Change

17 Mar 2021 07:01

RNS Number : 4998S
Anpario PLC
17 March 2021
 

Anpario plc

("Anpario" or the "Group")

 

Directorate change

 

Anpario, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity is pleased to announce the appointment of Marc Wilson as Group Finance Director with effect from 1 July 2021.

 

Following Karen Prior's request to relinquish the role of Group Finance Director a succession planning exercise was undertaken during 2020. The Nomination Committee unanimously approved the selection of Marc Wilson as Group Finance Director and recommended his appointment to the Board with effect from 1 July 2021. Karen will remain as an Executive Director of the Group responsible for Corporate Social Responsibility and as Company Secretary.

 

Marc has been part of Anpario's multi-faceted internal development programme and has worked closely with Karen and the Board on matters of strategic finance for the Group in recent years.

 

Marc is a member of the Chartered Institute of Management Accountants and currently Group Management Accountant as part of the Executive Management team for Anpario. Marc joined Anpario in 2010 and his responsibilities have included the development and rollout of Anpario's global ERP system and the accounting and integration of acquisitions during this time. He is currently Director of several UK and International subsidiaries of the Group.

 

Peter Lawrence, Chairman, stated:

 

"We are pleased to announce this further change to the Board which concludes a series of recent announcements forming part of a Board succession plan. Karen has been a dedicated and professional colleague since joining the Board in 2009 and will continue to work closely with Marc to ensure a smooth transition of his role. We welcome Marc to the Board and Karen's new role gives further strength to the Executive team and our focus on ESG matters."

 

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies:

 

Marc Charles Wilson (formerly Garner), aged 33, holds or has held the following directorships or partnerships in the past five years:

Current directorships/appointments

Agil Limited

Director

Anpario (Thailand) Ltd.

Director

Anpario Pty Ltd

Director

Anpario UK Limited

Director

Aquatice Limited

Director

Kiotech Limited

Director

Kiotechagil Limited

Director

Meriden Animal Health Limited

Director

Optivite International Limited

Director

Optivite Limited

Director

Orego-Stim Limited

Director

 

Past directorships/appointments

None

 

Marc Wilson currently holds 9,676 existing ordinary shares in Anpario, representing approximately 0.04% of the issued share capital of the Company. Marc also has options for a further 20,000 ordinary shares under the Joint Share Ownership Plan (the "JSOP" scheme) and 5,577 ordinary shares under The Anpario SAYE Share Option Scheme 2013.

 

There is no further information required to be disclosed under Rule 17 or Schedule 2(g) of the AIM Rules for Companies.

 

Anpario plc

Richard Edwards, CEO

+44(0) 777 6417 129

Karen Prior, Group Finance Director

+44(0) 1909 537380

Peel Hunt LLP (NOMAD)

+44 (0)20 7418 8900

Adrian Trimmings

Andrew Clark

Will Bell

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAFDXFDDFEEA
Date   Source Headline
18th Jun 20267:00 amRNSAGM Statement
11th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
9th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
20th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
19th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
15th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
14th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
13th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
12th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
11th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
8th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
7th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
6th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
5th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
1st May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
30th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20267:00 amRNSLaunch of Share Buyback Programme
10th Apr 202612:00 pmRNSInvestor Presentation via Investor Meet Company
31st Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSHolding(s) in Company
19th Jan 20263:44 pmRNSBlock listing return
19th Jan 20267:00 amRNSFull year trading statement
23rd Sep 20257:00 amRNSChange of Auditor
10th Sep 20257:00 amRNSInterim Results
9th Sep 202511:36 amRNSInvestor Presentation via Investor Meet Company
22nd Jul 20257:00 amRNSJSOP Awards and TVR
17th Jul 20251:15 pmRNSBlock listing return
19th Jun 20252:01 pmRNSResult of AGM
19th Jun 20257:00 amRNSAGM Statement
19th May 20255:33 pmRNSPosting of Annual Report and Notice of AGM
2nd May 20257:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSLaunch of Share Buyback Programme
2nd Apr 20257:00 amRNSAward Exercise, Voting Rights & Director Dealing
31st Mar 20257:00 amRNSFinal Results
26th Mar 20257:00 amRNSUpdate on Timing of Full Year Results Announcement
15th Jan 20257:00 amRNSGrant of options under SAYE Scheme
10th Jan 20257:00 amRNSFull year trading statement
9th Jan 20257:00 amRNSTotal Voting Rights
16th Dec 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
16th Dec 20247:00 amRNSLaunch of SAYE Scheme
29th Nov 20247:00 amRNSTotal Voting Rights
30th Sep 20247:00 amRNSAcquisition of Bio-Vet Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.